Loading
Latest filing published 04 Jun 2024 for Fusion Pharmaceuticals Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by John Valliant on record concern Fusion Pharmaceuticals Inc., in the capacity of chief executive. In total, 46 filings cover trades dated from 15 February 2022 to 4 June 2024.
Sales make up the whole of the open-market record (45 sales, €1.4M).
The latest filing, published on 4 June 2024, reports a transaction in Fusion Pharmaceuticals Inc. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations